Pasithea Therapeutics Corp (KTTA)

[$treet $inatra]

https://finance.yahoo.com/news/pasithea-therapeutics-announces-financial-business-201500938.html

 
 -- Cash Balance of $52.9 million to fund operations well into 2024 -- 
 -- Initiation of a drug development program in schizophrenia -- 
 -- Initiation of a drug development program in multiple sclerosis -- 
 -- Launched ketamine clinics in the U.K. and U.S. and expanded treatment options --

https://www.globenewswire.com/news-release/2022/03/08/2398871/0/en/Pasithea-Therapeutics-Announces-Collaboration-with-The-Glimpse-Group.html

https://www.benzinga.com/general/biotech/22/02/25388968/exclusive-pasithea-therapeutics-starts-new-multiple-sclerosis-vaccine-development-program

Weekly SAR @ $2.94 https://stockcharts.com/h-sc/ui?s=ktta&p=W&yr=1&mn=3&dy=0&id=p30814693576

NASDAQ 13.2M O/S https://www.otcmarkets.com/stock/KTTA/security

$52M cash on hand versus $25M market cap. Trading below cash value.

CEO exercised options to add 200k shares at $1.44.

Insiders (34.5%) shares are locked up til March. No risk of dumping.

Average share cost from retail is $4.53.

https://www.pasithea.com